

DAFTAR PUSTAKA

1. Starr SR, Roberts TT, Fischer PR. Osteogenesis imperfecta: Primary care. *Pediatr Rev.* 2010;31.
2. Marini JC, Forlino A, Cabral WA, Barnes AM, Antonio JDS, Milgrom S, et al. Consortium for Osteogenesis Imperfecta Mutations in the Helical Domain of Type I Collagen: Regions Rich in Lethal Mutations Align With Collagen Binding Sites for Integrins and Proteoglycans. *Hum Mutat.* 2007;28:209–21.
3. Rauch F, Glorieux FH. Osteogenesis imperfecta. *Lancet.* 2004;363:1377–85.
4. Smith R. Severe osteogenesis imperfecta: New therapeutic options? *Br Med J.* 2001;322:63–4.
5. Roughley PJ, Rauch F, Glorieux FH, Hofstetter W, Alini M. Osteogenesis imperfecta - Clinical and molecular diversity. *Eur Cells Mater.* 2003;5:41–7.
6. Marini JC. Osteogenesis Imperfecta. In: Kliegman RM, III JWSG, Shah SS, Tasker RC, Wilson KM, Behrman RE, editors. *Nelson Textbook of Pediatrics.* 21st ed. Philadelphia: Elsevier Inc; 2019. p. 14415–30.
7. Root AW, Diamond Jr. FB. Disorders of Mineral Homeostasis in Children and Adolescents. In: Sperling MA, editor. *Pediatric Endocrinology.* 4th ed. Philadelphia: Elsevier Saunders; 2014. p. 734–845.
8. Gajko-Galicka A. Mutations in type I collagen genes resulting in osteogenesis imperfecta in humans. *Acta Biochim Pol.* 2002;49:433–41.
9. Nussbaum RL, McInnes RR, Willard HF. The Molecular, Biochemical, and Cellular Basis of Genetic Disease. In: Thompson & Thompson Genetics in Medicine. 8th ed. Philadelphia: Elsevier Inc.; 2016. p. 215–55.
10. Pillion JP, Vernick D, Shapiro J. Hearing Loss in Osteogenesis Imperfecta: Characteristics and Treatment Considerations. *Genet Res Int.* 2011;2011:1–6.
11. Shapiro JR, Stover ML, Burn VE, McKinsty MB, Burshell AL, Chipman

- SD, et al. An osteopenic nonfracture syndrome with features of mild osteogenesis imperfecta associated with the substitution of a cysteine for glycine at triple helix position 43 in the pro α 1(I) chain of type I collagen. *J Clin Invest.* 1992;89:567–73.
12. Imani P, Vijayasekaran S, Lannigan FJ. Is it necessary to screen for hearing loss in the paediatric population with osteogenesis imperfecta? *Clin Otolaryngol Allied Sci.* 2003;28:199–202.
 13. Forlino A, Cabral WA, Barnes AM, Marini JC. New perspectives on osteogenesis imperfecta. *Nat Rev Endocrinol* [Internet]. 2011;7:540–57. Available from: <http://dx.doi.org/10.1038/nrendo.2011.81>
 14. Glorieux F. Guide to Osteogenesis Imperfecta. *Osteoporos Relat Bone Dis ~ Natl Resour Cent.* 2007;30.
 15. Ooi HL, Briody J, Biggin A, Cowell CT, Munns CF. Intravenous zoledronic acid given every 6 months in childhood osteoporosis. *Horm Res Paediatr.* 2013;80:179–84.
 16. Unal E, Abaci A, Bober E, Buyukgebiz A. Oral alendronate in osteogenesis imperfecta. *Indian Pediatr.* 2005;42:1158–60.
 17. DiMeglio LA, Ford L, McClintock C, Peacock M. A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta. *J Pediatr Endocrinol Metab.* 2005;18:43–53.
 18. DiMeglio LA, Peacock M. Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. *J Bone Miner Res.* 2006;21:132–40.
 19. Tsimicalis A, Denis-Larocque G, Michalovic A, Lepage C, Williams K, Yao TR, et al. The psychosocial experience of individuals living with osteogenesis imperfecta: a mixed-methods systematic review. *Qual Life Res.* 2016;25:1877–96.
 20. Shea-Landry GL, David MA, Cole EC. Psychosocial aspects of osteogenesis imperfecta. *CMAJ.* 1986;135:Vol. 135 (977-981).
 21. Monti E, Mottes M, Fraschini P, Brunelli P, Forlino A, Venturi G, et al. Current and emerging treatments for the management of osteogenesis

- imperfecta. *Ther Clin Risk Manag.* 2010;6:367–81.
22. de Graaff F, Verra W, Pruijs JEH, Sakkers RJB. Decrease in outpatient department visits and operative interventions due to bisphosphonates in children with osteogenesis imperfecta. *J Child Orthop.* 2011;5:121–5.
 23. Gauld LM, Kappers J, Carlin JB, Robertson CF. Height prediction from ulna length. *Dev Med Child Neurol.* 2004;46:475–80.
 24. Folkestad L, Hald JD, Ersbøll AK, Gram J, Hermann AP, Langdahl B, et al. Fracture Rates and Fracture Sites in Patients With Osteogenesis Imperfecta: A Nationwide Register-Based Cohort Study. *J Bone Miner Res.* 2017;32:125–34.
 25. Anissipour AK, Hammerberg KW, Caudill A, Kostiuk T, Tarima S, Zhao HS, et al. Behavior of scoliosis during growth in children with osteogenesis imperfecta. *J Bone Jt Surg.* 2014;96:237–43.
 26. Zambrano MB, Brizola ES, Refosco L, Giugliani R, Félix TM. Anthropometry, Nutritional Status, and Dietary Intake in Pediatric Patients with Osteogenesis Imperfecta. *J Am Coll Nutr.* 2014;33:18–25.
 27. Varni JW. Scaling and scoring of the Pediatric Quality of Life Inventory. *Mapi Res Trust.* 2017;17:1–146.